单日狂揽4．65亿元，高人气创新药“新势力”——520880规模升值9．8亿元！标的指数官宣剔除CXO

Group 1 - The core viewpoint of the article highlights the recent fluctuations in the Hong Kong Stock Connect Innovative Drug ETF (520880), which saw a peak increase of over 3% before closing down by 1.6% on July 31 [1] - Despite market volatility, there is strong investor enthusiasm, with a significant inflow of funds amounting to 4.65 billion CNY on a single day, and a total net inflow of 6.59 billion CNY over three days [1][2] - The fund's scale has surged to 9.86 billion CNY, representing a 140% increase since its launch on July 7 [1][2] Group 2 - The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on the innovative drug industry chain, primarily comprising innovative drug research and development companies [4] - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has seen a cumulative increase of 101.58% year-to-date as of July 31, significantly outperforming the Hang Seng Index and the Hang Seng Technology Index by 78.08 and 79.53 percentage points, respectively [6][7] - The index will undergo a significant adjustment to exclude companies primarily engaged in CXO services, thereby focusing solely on innovative drug R&D firms, enhancing its purity to 100% [8][11] Group 3 - The ongoing trend in the innovative drug sector is driven by the increasing number of outbound orders and the realization of commercial profits, with over 50 transactions amounting to more than 48 billion USD in the first half of 2025 [11] - The differentiation between innovative drug companies and CXO service providers is crucial, as CXOs do not directly reflect the international competitiveness of Chinese innovative drugs [11] - The adjustment in the index composition is expected to mitigate the impact of CXOs on the innovative drug market, showcasing a more robust upward trend in the industry [11]